GLP1R and Alzheimer disease: A recent Cochrane review proposed that there is no or very little difference between RCTs and observational studies when heterogeneity is low (<50%).97 While we do not have RCT evidence for glitazones, our meta-analyses I2 were consistently 0%, even in sensitivity analyses where we included studies with Alzheimer's dementia as an outcome.97 Studies could also investigate on what dose and length of drug use of GLP-1 RAs would be ideal in reducing the risk of dementia.